New study evaluates effectiveness of weight loss surgery in individuals with obesity, diabetes
Obesity is linked to increased risk of heart disease, diabetes, and chronic liver disease, as well as other disorders.
Yale researchers report Jan. 10 in the journal Nature Communications that they have found the molecular regulator of this fat droplet doorman, and potential new treatments for obesity based on restoring healthy balance found in lean individuals.
The regulator, or commander, of these fat droplet sentinels is an enzyme called O-GlcNAc transferase (OGT), according to the research team. Mice lacking the enzyme are lean, exhibit a dramatic reduction in the size of fat cells and tend to burn off lipids first rather than taking in more carbohydrate fuel.
Conversely, the overexpression of OGT in mice triggers obesity by increasing intake of carbohydrates without burning off excess lipids.
The commander of this doorman makes it easier for nutrients to get in, but harder for lipids to get out." Xiaoyong Yang, associate professor of comparative medicine and of cellular and molecular physiology, Yale University School of Medicine
Yang is also the senior author.
In previous studies, Yang's team found that overexpression of OGT in fat cells has another side effect -- it signals the brain to consume more calories (essentially asking the brain to order another pizza).
"This makes OGT a very attractive target to pharmaceutically treat obesity," Yang said.
Yale's Yunfan Yang is first author of the study, which was primarily funded by the National Institutes of Health. Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology